Patent ID: 6545160
Filing Date: 2003-04-08
Classification: A61P,C07C,C07D

Abstract:
A compound of Formula I: wherein:A together with â€”CHâ€” and W forms a heterocyclic or substituted heterocyclic group; Q is selected from the group consisting of alkylene, substituted alkylene, â€”COâ€”, â€”NR5â€” (where R5 is hydrogen, alkyl, or acyl), â€”Oâ€”, or â€”S(O)q where q is an integer from 0 to 2; W is â€”CHâ€”or â€”Nâ€”; Z is â€”Oâ€”or â€”Sâ€”; R1 is selected from the group consisting of aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, and substituted cycloalkyl; R2 is selected from the group consisting of hydrogen, alkyl which is optionally substituted with one to four substituents independently selected from Ra and Cy which is optionally substituted with one to four substituents independently selected from Rb wherein Ra and Rb are as defined below; R3 is selected from the group consisting of: (a) -(alkylene)-Arâ€”R6, -(alkenylene)-Arâ€”R6, or -(alkynylene)-Arâ€”R6 where: Ar is selected from the group consisting of aryl, heteroaryl, or heterocyclic wherein said aryl, heteroaryl, and heterocyclic rings are optionally substituted with one or two substituents independently selected from Ra wherein Ra is as defined below; R6 is selected from the group consisting of â€”Oâ€”Yâ€”NR7R8 and â€”Oâ€”Yâ€”R9 wherein Y is selected from the group consisting ofâ€”C(O)â€” and â€”SO2â€”; R7 and R8 are independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, heterocyclic, and substituted heterocyclic; or R7 and R8 are joined to form a heterocycle or substituted heterocycle; and R9 is heterocycle or substituted heterocycle; (b) -(alkyene)-Ar2â€”Ar1,-(alkenylene)-Ar2-Ar1 and -(alkynylene)-Ar2â€”Ar1, wherein Ar1 and Ar2 are independently aryl or heteroaryl each of which is optionally substituted with one to four substituents independently selected from Rb as defined below; and alkylene, alkenylene and alkynylene are optionally substituted with one to four substituents independently selected from Ra as defined below; R4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, aryl-C1-10alkyl, heteroaryl, and heteroaryl-C1-10 alkyl wherein alkyl, alkenyl and alkynyl are optionally substituted with one to four substituents selected from Ra as defined below; and aryl and heteroaryl are optionally substituted with one to four substituents independently selected from Rb as defined below; Ra is selected from the group consisting of Cy, â€”ORd, â€”NO2, halogen, â€”S(O)mRd, â€”SRd, â€”S(O)2ORd, â€”S(O)mNRdRe, â€”NRdRe, â€”O(CRfRg)nNRdRe, â€”C(O)Rd, â€”CO2Rd, â€”CO2(CRfRg)nCONRdRe, â€”OC(O)Rd, â€”CN, â€”C(O)NRdRe, â€”NRdC(O)Re, â€”OC(O)NRdRe, â€”NRdC(O)ORe, â€”NRdC(O)NRdRe, â€”CRd(Nâ€”ORe), CF3, and â€”OCF3; wherein Cy is optionally substituted with one to four substituents independently selected from Rc wherein: Rc is selected from the group consisting of halogen, amino, carboxy, C1-4 alkyl, C1-4 alkoxy, aryl, aryl-C1-4 alkyl, hydroxy, CF3, and aryloxy; Rd and Re are independently selected from hydrogen, alkyl, alkenyl, alkynyl, Cy and Cy-alkyl wherein alkyl, alkenyl, alkynyl and Cy are optionally substituted with one to four substituents independently selected from Rc; or Rd and Re together with the atoms to which they are attached form a heterocyclic ring of 5 to 7 atoms and containing 0-2 additional heteroatoms independently selected from oxygen, sulfur and nitrogen; and Rf and Rg are independently selected from hydrogen, alkyl, Cy and Cy-alkyl; or Rf and Rg together with the carbon to which they are attached form a ring of 5 to 7 atoms containing 0-2 heteroatoms independently selected from oxygen, sulfur and nitrogen; Rb is selected from the group consisting of Ra as defined above, alkyl, alkenyl, alkynyl, aryl-C1-10 alkyl, heteroaryl-C1-10 alkyl, wherein alkyl, alkenyl, alkynyl, aryl, heteroaryl are optionally substituted with a group independently selected from Rc; Cy is cycloalkyl, heterocyclyl, aryl, or heteroaryl; and R10 is selected from the group consisting of â€”C(O)ORd, â€”P(O)(ORd)(ORe), â€”P(O)(Rd)(ORe), â€”S(O)mORd, â€”C(O)NRdRh, and -5-tetrazolyl where: Rd and Re are as defined above; Rh is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cyano, aryl, aryl-C1-10 alkyl, heteroaryl, heteroaryl-C1-10 alkyl, or â€”SO2Ri wherein alkyl, alkenyl, and alkynyl are optionally substituted with one to four substitutents independently selected from Ra; and aryl and heteroaryl are each optionally substituted with one to four substituents independently selected from Rb where Ra and Rb are as defined above; Ri is selected from the group consisting of alkyl, alkenyl, alkynyl, and aryl wherein alkyl, alkenyl, alkynyl and aryl are each optionally substituted with one to four substituents independently selected from Rc; m is an integer from 1 to 2; and n is an integer from 1 to 10; or pharmaceutically acceptable salts, individual isomer, mixtures of isomers, and prodrugs thereof.